# iSiP

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/isip

- Industry: Biotechnology
- Headquarters: Tokyo, Japan
- Website: https://corp.i-sip.jp
- Total disclosed funding: $6M
- Latest round: Series A (May 21, 2025)
- Investors on record: 3

## About

Founded in 2022 and based in Tokyo, Japan, iSiP, Inc. operates a drug discovery DX platform that discovers and optimizes lead compounds using compound design AI. In May 2025, iSiP, Inc. raised JPY 650 million in series A funding led by new investor DNX Ventures. Returning investor Deepcore also participated in this round.

The company is developing an AI-driven platform that integrates AI algorithms and physical simulations, enabling researchers to expedite drug development, identify novel compounds, and enhance the overall efficiency of pharmaceutical research. The firm’s platform accelerates the creation of new drugs and promotes the growth of a sustainable domestic research ecosystem.

The company plans to use the May 2025 funding to improve its digital drug development engine and invest in the clinical studies of its new medicines.

## Funding rounds

- Series A, May 21, 2025, $4.5M — DNX Ventures, Deepcore
- Seed, Aug 22, 2023, $1.6M — Deepcore, D3 LLC

## Investors

- Deepcore (https://capitalatlas.ai/funds/deepcore) — Seed, Series A
- D3 LLC (https://capitalatlas.ai/funds/d3-llc) — Seed
- DNX Ventures (https://capitalatlas.ai/funds/dnx-ventures) — Series A